Article Text
Statistics from Altmetric.com
Footnotes
Twitter @Kieranfdocherty, @markcpetrie20
Contributors Both authors contributed equally to this manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests KFD reports that his employer, the University of Glasgow, has been rumunerated by AstraZeneca for his work relating to the DAPA-HF trial and he has received honoraria from AstraZeneca and Eli Lilly. MCP reports research support or consultancy from Boehringer Ingelheim, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Vifor, Pharmacosmos, AbbVie, Bayer, Takeda, Cardiorentis and Siemens. MCP is supported by The British Heart Foundation grant RE/18/6/34217.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Author note References which include a * are considered to be key references.